These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17428852)

  • 21. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
    Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
    J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.
    Pichla-Gollon SL; Lin SW; Hensley SE; Lasaro MO; Herkenhoff-Haut L; Drinker M; Tatsis N; Gao GP; Wilson JM; Ertl HC; Bergelson JM
    J Virol; 2009 Jun; 83(11):5567-73. PubMed ID: 19279092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
    Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG
    Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
    Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
    J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Novel Vaccines Against Infectious Diseases Based on Chimpanzee Adenoviral Vector.
    Zhang C; Chi Y; Zhou D
    Methods Mol Biol; 2017; 1581():3-13. PubMed ID: 28374240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
    Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
    J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35.
    Sakurai F; Nakashima K; Yamaguchi T; Ichinose T; Kawabata K; Hayakawa T; Mizuguchi H
    J Control Release; 2010 Dec; 148(2):212-8. PubMed ID: 20800630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
    Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
    J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.
    Dicks MD; Spencer AJ; Coughlan L; Bauza K; Gilbert SC; Hill AV; Cottingham MG
    Sci Rep; 2015 Nov; 5():16756. PubMed ID: 26576856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.
    Abbink P; Maxfield LF; Ng'ang'a D; Borducchi EN; Iampietro MJ; Bricault CA; Teigler JE; Blackmore S; Parenteau L; Wagh K; Handley SA; Zhao G; Virgin HW; Korber B; Barouch DH
    J Virol; 2015 Feb; 89(3):1512-22. PubMed ID: 25410856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
    Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
    J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys.
    Collignon C; Bol V; Chalon A; Surendran N; Morel S; van den Berg RA; Capone S; Bechtold V; Temmerman ST
    Front Immunol; 2020; 11():579872. PubMed ID: 33329551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenoviral vector expressing ICP47 inhibits adenovirus-specific cytotoxic T lymphocytes in nonhuman primates.
    Scaria A; Sullivan JA; St George JA; Kaplan JM; Lukason MJ; Morris JE; Plog M; Nicolette C; Gregory RJ; Wadsworth SC
    Mol Ther; 2000 Nov; 2(5):505-14. PubMed ID: 11082324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.
    Smaill F; Jeyanathan M; Smieja M; Medina MF; Thanthrige-Don N; Zganiacz A; Yin C; Heriazon A; Damjanovic D; Puri L; Hamid J; Xie F; Foley R; Bramson J; Gauldie J; Xing Z
    Sci Transl Med; 2013 Oct; 5(205):205ra134. PubMed ID: 24089406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
    Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
    J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
    Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
    Front Immunol; 2018; 9():335. PubMed ID: 29563911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.
    Vitelli A; Folgori A; Scarselli E; Colloca S; Capone S; Nicosia A
    Expert Rev Vaccines; 2017 Dec; 16(12):1241-1252. PubMed ID: 29047309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector.
    Haut LH; Ratcliffe S; Pinto AR; Ertl H
    J Infect Dis; 2011 Apr; 203(8):1073-81. PubMed ID: 21450997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors.
    Song W; Kong HL; Traktman P; Crystal RG
    Hum Gene Ther; 1997 Jul; 8(10):1207-17. PubMed ID: 9215738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.